CHANGE IN RATINGS

Amerigroup ( AGP coverage initiated at Jefferies: Jefferies is initiating coverage on AGP with a Hold rating. See sales growth around 20% for 2007 and 2008 factored into current valuation. Price target at $33.

Albemarle ( ALB - Get Report) downgraded at Jefferies:Jefferies is downgrading ALB to Hold from Buy due to softer 2007 fundamentals. See limited upside to shares. 2008 estimates cut to $4.10 from $4.20 and price target lowered to $55 from $60.

Applied Materials ( AMAT - Get Report) upgraded at Credit Suisse: Credit Suisse is upgrading AMAT to Outperform from Neutral based on leverage to the DRAM cycle. Raised target price to $20 from $18.

Charter Comm. ( CHTR - Get Report) downgraded at Citigroup: CHTR was downgraded from Buy to Hold at Citigroup. Stock is up significantly over the past two months, but there is little upside potential to the $1.75 price target.

Genentech ( DNA upgraded at Baird: DNA was upgraded from Neutral to Outperform at Robert Baird. $94 price target. Market over-reacted to delay in Avastin approval for breast cancer. In the meantime, recent data points to upside potential for other indications.

HealthSpring ( HS coverage initiated at Jefferies: Coverage initiated on HS with a Hold rating at Jefferies. See attractive valuation but limited visibility regarding ability to return to 2005 Medicare enrollment growth levels. $22 target price.

Humana ( HUM coverage initiated at Jefferies: Jefferies is initiating coverage on HUM with a Buy rating. Believe private fee for service Medicare plan is a more sustainable product than investors consider. Price target at $75.

IPSCO ( IPS upgraded at UBS: UBS is upgrading IPS to Buy from Neutral based on increasing exposure to energy tubulars after acquiring NS Group. Raised target price to $105 from $104.

Lone Star Tech ( LSS upgraded at Bear: LSS was upgraded from Peer Perform to Outperform at Bear Stearns. Recent takeovers in the industry suggest the company is undervalued. LSS also recently made a smart investment in a Chinese plant. $60 price target.

Plum Creek Timber ( PCL downgraded at Morgan Stanley: PCL was downgraded from Equal-weight to Underweight, at Morgan Stanley. $32 price target. Now expect a sharp pullback in residential construction, which will cut the value of timber.

WellCare Health ( WCG coverage initiated at Jefferies: WCG coverage initiated with a Hold rating at Jefferies. Unique strategy as diversified government-focused health plan allows flexibility. See 30% growth rate attainable. Price target at $63.

STOCK COMMENTS / EPS CHANGES

Air Products ( APD - Get Report) estimates increased at Jefferies: Jefferies is upping its 2006 estimates on APD by 2 cents to $3.53 based on anticipated $1.5B share repurchase plan as well as slowdown in electronics segment in 2007. Reiterated Buy with $77 target.

Coca-Cola Enterprises ( CCE numbers lowered at Morgan Stanley: Shares of CCE now seen reaching $23.50 at Morgan Stanley. Estimates also cut, to reflect higher aluminum costs. Overweight rating.

Campbell Soup ( CPB estimates increased at Goldman: CPB 2007 estimates upped to $1.84 from $1.82 at Goldman. Company beat Q4 estimates by 2 cents ($0.20 vs. $0.18). See shares fairly valued, maintaining Neutral rating.

Gannett ( GS estimates lowered at Goldman Sachs: Goldman is lowering its 2006 estimate on GCI by 4 cents to $4.96, based on weak August revenues in newspaper ad sales, particularly for help wanted section. Price target cut to $60 from $63 and maintained Neutral rating.

Gold Fields ( GFI target raised at Goldman Sachs: Goldman is raising its price target on GFI to $20 from $19 after company announced deepening of two South African mines, to access additional 10.8 million ounces of gold. Maintain Neutral rating.

Qualcomm ( QCOM added to Focus List at Cowen: QCOM was added to the Focus List at Cowen. Channel checks show that the U.S. business is improving. The supply of CDMA chips is also tightening. Outperform rating.

Cimarex ( XEC target price raised at UBS: UBS is raising its target price on XEC to $48 from $45.50 based on valuation. Maintained Buy rating.